Stable (n = 51) | Unstable (n = 19) | p - value | |
---|---|---|---|
Demographics | |||
Gender (% Male) | 72.5 | 52.6 | 0.15 |
Pack years | 45.0 [10.0–220.0] | 52.0 [10.0–113.0] | 0.67 |
Smoking status (% Current) | 37.3 | 36.8 | 1.00 |
BMI (Kg/m2) | 27.2 [17.3–49.2] | 27.9 [20.7–45.0] | 0.28 |
FFMI (Kg/m2) | 17.8 (3.4) | 18.7 (3.4) | 0.34 |
Chronic bronchitis (%) | 58.3 | 61.1 | 1.00 |
Exacerbations (1 year prior) | 0.0 [0.0–1.0] | 0.0 [0.0–1.0] | 0.88 |
Co-morbidities | |||
Cardiovascular comorbidity any (%) | 94.1 | 94.7 | 1.00 |
Comorbidities any (%) | 94.1 | 94.7 | 1.00 |
Patient reported outcomes | |||
SGRQ total | 40.1 [14.6–80.0] | 50.0 [22.2–82.3] | 0.019 |
SGRQ symptoms | 55.1 [22.0–91.0] | 60.8 [15.4–90.0] | 0.10 |
SGRQ impact | 26.0 [2.5–71.6] | 35.9 [9.0–73.7] | 0.20 |
SGRQ activity | 59.3 [7.6–100.0] | 79.0 [15.6–100.0] | 0.003 |
CAT | 14.0 [4.0–28.0] | 21.0 [8.0–39.0] | 0.006 |
CES-D | 11.0 [1.0–32.0] | 12.5 [3.0–38.0] | 0.94 |
Functional capacity | |||
6MWD (metres) | 425.3 (98.5) | 361.5 (124.8) | 0.06 |
Lung function | |||
Vital capacity % | 103.3 (19.8) | 96.6 (16.5) | 0.25 |
Total lung capacity % | 108.8 (19.9) | 111.8 (24.6) | 0.65 |
Residual volume % | 130.9 (37.4) | 150.4 (60.2) | 0.16 |
Inspiratory capacity % | 87.0 (23.0) | 89.8 (16.1) | 0.67 |
FRC % | 129.3 (30.7) | 134.2 (44.5) | 0.65 |
DLCO % | 66.2 (20.3) | 64.1 (24.3) | 0.76 |
KCO % | 75.5 [41.2–137.0] | 81.5 [35.0–124.0] | 0.97 |
VA % | 82.8 (12.0) | 79.2 (9.3) | 0.32 |
Post FEV1 % | 69.7 (11.7) | 62.4 (9.0) | 0.016 |
Reversibility % | 5.0 [−3.0–+33.0] | 7.4 [0.8–32.0] | 0.47 |
Reversibility mls | 90.0 [−40.0–+670.0] | 95.0 [20.0–+380.0] | 0.90 |
Bacteriology | |||
Bacterial load (genome copies/ml) | 1.44 × 105 [0.0–2.43 × 108] | 7.4 × 102 [0–10.4 × 107] | 0.66 |
Colonised (% >1 × 104 total PPM) | 66.7 | 46.2 | 0.30 |
Systemic inflammation | |||
CRP (mg/L) | 3.0 [1.0–35.5] | 4.5 [1.0–157.0] | 0.06 |
WBC (109/L) | 7.2 [5.4–12.6] | 7.4 [5.0–12.6] | 0.42 |
Eosinophils (109/L) | 0.2 [0.0–0.9] | 0.2 [0.1–0.3] | 0.32 |